|Bid||55.26 x 1100|
|Ask||62.50 x 1100|
|Day's Range||60.19 - 60.49|
|52 Week Range||55.61 - 70.39|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||0.00|
|Expense Ratio (net)||0.25%|
With the Federal Reserve continuing its course of raising interest rates, some investors may think income stocks and the related exchange-traded funds (ETFs) are vulnerable or destined to produce lagging returns. On the back of recent strength, the Vanguard Dividend Appreciation ETF (NYSEARCA:VIG), the largest U.S. dividend ETF by assets, is up 11.3% year-to-date, just ahead of the 10.8% returned by the S&P 500. When it comes to income stocks, data suggest there is more good news than bad on the dividend growth front.
Rising interest rates can be a bane for dividend stocks and high-yielding, income-oriented sectors, but there is some positive news in the 2018 dividend outlook. Through the first half of the year, approximately 40% of S&P 500 member firms boosted dividends, potentially making some of the best funds to buy in the dividend landscape all the more attractive. Looked at differently, some of the best funds to buy need to show investors that dividend stocks are worth the extra risk relative to safer U.S. government debt.
International stocks, both of the developed and emerging markets varieties, are disappointing this year. The MSCI EAFE Index and the MSCI Emerging Markets Index, two of the most widely followed gauges of ex-U.S. equities, are both in the red while the S&P 500 is up about 7 percent. The Vanguard International Dividend Appreciation ETF (NASDAQ: VIGI) is modestly higher on a year-to-date basis.
Dividend investors looking to add some international income to their portfolios have plenty of exchange traded funds to consider. VIGI, which debuted in March 2016, is the international answer to the popular Vanguard Dividend Appreciation ETF (NYSEArca: VIG ) , the largest U.S. dividend ETF. VIGI has rapidly gained a following with investors.
The S&P 500 gained 2.5% in the first half of the year, delivering a decent though not jaw-dropping performance. With the second half of the year, now could be an ideal time for some investors to consider reconfiguring their portfolios or buy some of the first half’s outperforming (or laggard) funds.
E*TRADE Financial Corporation today announced it has surpassed 250 commission-free ETFs with the addition of 46 ETFs from six providers to its Commission-Free ETF Pr
Investors often have a domestic bias, meaning their portfolios are usually heavily allocated to assets in their native countries. The same is true of dividend investors, who tend to focus on U.S. dividend-paying stocks.
Enbridge (ENB) is involved in energy transportation in the United States and Canada. Transportation and other services drove the growth in 2016, offset by commodity sales and gas distribution sales. All of these segments fueled growth in 9M17. The Liquids Pipelines, Green Power, and Transmission segments drove growth in 2016, offset by Gas Distribution, Gas Pipelines, and Processing and Energy Services.
Novartis’s (NVS) Crizanlizumab is an investigational humanized monoclonal antibody that binds P-selectin on the covering of endothelial and platelet cells in blood vessels leading to P-selectin blockade. Vaso-occlusive crises occur episodically when sickle-shaped red blood cells inhibit blood flow through blood vessels. The clinical inhibition of P-selectin may prevent painful vaso-occlusion in small blood vessels and maintain blood flow.
The Federal Reserve hiked interest rates three times last year and more rate increases are expected this year. Still, 10-year Treasuries yield less than 2.7%, underscoring a nearly four-decade downtrend in U.S. borrowing costs. For its part, the S&P 500 yields an anemic 1.8%.